Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.


January 15, 2021
PresentationTivozanib

ASCO GI 2021: DEDUCTIVE: a Study of Tivozanib in Combination with Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma; Phase Ib results

September 29, 2020
PublicationTivozanib

TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

Authors: L. Albiges, P. Barthélémy, M. Gross-Goupil, S. Negrier, M. N. Needle, B. Escudier. Click here for link to article.

September 13, 2020
PublicationTivozanib

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Authors: Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, Daniel Powers, David F. McDermott, Brian I. Rini. Click here for link to article.

June 11, 2020
PublicationFiclatuzumab

A Multicentre Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

Authors: Julie E. Bauman, James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, Autumn Gaither-Davis, Jennifer R. Grandis, Laura P. Stabile. Click here for link to article.

May 29, 2020
PresentationTivozanib

ASCO 2020: TIVO-3: Final OS analysis of a randomized, controlled, multi-center, open-label phase 3 study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC)

January 27, 2020
PresentationFiclatuzumab

ASCO GI 2020: Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab in Patients with Advanced Pancreatic Cancer

1 3 4 5 6 7 14